{"ticker": {"uuid": "28892bef-39e4-4e3c-b8a9-4540fd6a4682", "symbol": "ARTV", "name": "Artiva Biotherapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Ra Capital Management funds buy $194k in Artiva Biotherapeutics stock By Investing.com", "summary": "RA Capital Management funds recently acquired an additional $194,039 worth of Artiva Biotherapeutics (NASDAQ:ARTV) common stock over two days, increasing their already significant stake. These purchases involved shares bought at prices ranging from $8.94 to $8.97, even as Investi", "url": "https://m.za.investing.com/news/stock-market-news/ra-capital-management-funds-buy-194k-in-artiva-biotherapeutics-stock-93CH-4369073?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-15T00:12:25", "published_display": "15 Jul 2026 00:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra Capital Management funds buy $194k in Artiva Biotherapeutics stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOcXNYUmZkYTJzTm5SVmR5ZlF0cHltblpyam9IeUF5bkRQRDdIYjRZYWEtblZmN3RvekgxeDN4STUxcVNMc3Baem9PZVBvZXNoa0Q0dHg3amlyWkIyT0t4SlFsY3RsNk5FZkx2QVQ5M3o3aGJ0ZU44bFluUEFxQ3VMWnU4YU5BYXphbFJuX2F1TFJkc0Zyb2dXTEU0ZXFEWklHU3FNZFBKWlJQSjVRM2VmVGlfSXBrX2R2Y19oYWltOWRjN2IzMGtrbQ?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-14T23:04:00+00:00", "published_display": "14 Jul 2026 23:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?", "summary": "Artiva Biotherapeutics, Inc. (ARTV) is significantly outperforming the Medical sector and its specific industry (Medical - Biomedical and Genetics) this year, with a year-to-date return of 121% compared to the sector's 2.8% and the industry's 7.4%. The company holds a Zacks Rank ", "url": "https://finance.yahoo.com/healthcare/articles/artiva-biotherapeutics-inc-artv-outperforming-134002494.html", "source_name": "Market source", "published_at": "2026-07-08T08:40:00", "published_display": "08 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Artiva Biotherapeutics, Inc. (ARTV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1MZFlINzg4dmQzN1BlSDR4ZDdkNnMxNmlrN2x5THVuNXAzS2xPZnJjUWdXVk5iMnl0UmF6UExwQnB6NnVZekZiTHczc1NMS1dZZUFWanUxRXl2VTFvQkp6SWMwYkd0QzE4UlgyYQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What date does Artiva Biotherapeutics, Inc.'s (ARTV) report Earnings - Earnings Calendar & Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTFBnYnVIeTJCOFdFemFxOVNrUTdpM3dxVHhRVF9tenJVaGg4a1NYb1ZGbFh3UUhuaU00b0lXd3JUVWJHZ21zVHA1b2pHdjhrbi11ZmpHMzU4a2E3OUx1dnhIdE9wVXB2RmZ3cEhr?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Artiva Biotherapeutics Inc For: 29 June By Investing.com", "summary": "This article reports on a Form 4 filing for Artiva Biotherapeutics Inc (ARTV) for June 29, 2026. Form 4 filings typically disclose transactions by corporate insiders. The article provides the date of the filing and mentions the company's stock symbol and current trading performan", "url": "https://ng.investing.com/news/stock-market-news/form-4-artiva-biotherapeutics-inc-for-29-june-93CH-2578839", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T08:42:17", "published_display": "30 Jun 2026 08:42", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra capital funds buy $292k Artiva Biotherapeutics stock in late June", "summary": "Investment funds associated with RA Capital Management, L.P. recently purchased approximately $292,126 worth of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) stock. This comes as Artiva's shares have surged over 554% in the last year, and the company has received a Regenerative Medi", "url": "https://www.investing.com/news/insider-trading-news/ra-capital-funds-buy-292k-artiva-biotherapeutics-stock-in-late-june-93CH-4766254", "source_name": "Investing.com", "published_at": "2026-06-29T21:42:17", "published_display": "29 Jun 2026 21:42", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Index", "summary": "Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV) has been added to the Russell 2000 Index, as well as several related Russell indices including the Russell 2500 Growth, Russell 2000 Value, and Russell 3000 Index. This inclusion marks a significant milestone for the clinical-stage bi", "url": "https://www.marketscreener.com/news/artiva-biotherapeutics-inc-nasdaqgm-artv-added-to-russell-2000-index-ce7f5fdfdc8fff27", "source_name": "marketscreener.com", "published_at": "2026-06-29T17:52:00", "published_display": "29 Jun 2026 17:52", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Value Benchmark", "summary": "Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV) has been added to the Russell 2000 Value Benchmark. The company is a clinical-stage biotechnology firm specializing in natural killer (NK) cell-based therapies for autoimmune diseases and cancers. Its lead product candidate, AlloNK, i", "url": "https://www.marketscreener.com/news/artiva-biotherapeutics-inc-nasdaqgm-artv-added-to-russell-2000-value-benchmark-ce7f5fdfd880ff27", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:39:53", "published_display": "29 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 3000E Growth Benchmark", "summary": "Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV) has been added to the Russell 3000E Growth Benchmark. This move signifies recognition within a broad market index, suggesting increased visibility and potential for investment. The company specializes in developing clinical-stage, nat", "url": "https://www.marketscreener.com/news/artiva-biotherapeutics-inc-nasdaqgm-artv-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8cf120", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:39:52", "published_display": "29 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Growth Benchmark", "summary": "Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV), a clinical-stage biotechnology company, has been added to the Russell 2000 Growth Benchmark index. This inclusion highlights the company's focus on developing NK cell-based therapies for autoimmune diseases and cancers. The article a", "url": "https://www.marketscreener.com/news/artiva-biotherapeutics-inc-nasdaqgm-artv-added-to-russell-2000-growth-benchmark-ce7f5fded18df121", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:33:00", "published_display": "29 Jun 2026 07:33", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Artiva Biotherapeutics, Inc. \u2013 NASDAQ:ARTV", "summary": "This article provides financial information for Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or an incomplete data point from a financial charting platform like TradingView, with no further details", "url": "https://www.tradingview.com/symbols/NASDAQ-ARTV/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:11:17", "published_display": "28 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Artiva Biotherapeutics, Inc. \u2013 NASDAQ:ARTV", "summary": "The article provides a title related to the \"Price to book forward\" for Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) and lists various financial and market data services and tools available on the TradingView platform. However, the body of the article appears to primarily consist ", "url": "https://www.tradingview.com/symbols/NASDAQ-ARTV/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T15:10:25", "published_display": "28 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Artiva Biotherapeutics, Inc. \u2013 NASDAQ:ARTV", "summary": "This page displays the enterprise value to EBITDA forward for Artiva Biotherapeutics, Inc. (NASDAQ: ARTV). It presents financial data, market information, and related company details. The content is primarily a data presentation from TradingView, including a historical overview, ", "url": "https://www.tradingview.com/symbols/NASDAQ-ARTV/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:41:39", "published_display": "27 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference", "summary": "Artiva Biotherapeutics announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. Management will host a fireside chat on June 30, 2026, to discuss the company's clinical-stage cell therapies for autoimmune diseases, including their lead progra", "url": "https://finance.yahoo.com/healthcare/articles/artiva-biotherapeutics-participate-h-c-200500499.html", "source_name": "Market source", "published_at": "2026-06-26T22:10:17", "published_display": "26 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARTV Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast for Artiva Biotherapeutics, Inc. (ARTV) stock, including analyst price targets, historical performance, earnings information, and financial data. It highlights that analysts have a maximum price estimate of $41.00 and a minimum of $23.00 ", "url": "https://www.tradingview.com/symbols/NASDAQ-ARTV/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:10", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics, Inc. Actuals & Estimates (NASDAQ:ARTV)", "summary": "This article provides a detailed financial overview and analyst estimates for Artiva Biotherapeutics, Inc. (NASDAQ: ARTV). It covers the company's financial performance, stock price movements, future forecasts, and key metrics such as market capitalization and earnings reports. T", "url": "https://www.tradingview.com/symbols/NASDAQ-ARTV/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:10", "published_display": "25 Jun 2026 18:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Inc (ARTV) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Artiva Biotherapeutics Inc (ARTV), which currently holds a weak financial score of 5.40, ranking low within the Biotechnology & Medical Research industry. Key financial metrics related to profitability, operational efficiency, and gro", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-artv/financial-health", "source_name": "TradingKey", "published_at": "2026-06-24T06:11:10", "published_display": "24 Jun 2026 06:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA CAPITAL MANAGEMENT, L.P. Increases Stake in Artiva Biotherape", "summary": "RA CAPITAL MANAGEMENT, L.P. has significantly increased its stake in Artiva Biotherapeutics Inc. by acquiring an additional 1,434,155 shares. This transaction, executed on June 11, 2026, at $8 per share, brings their total holdings to 17,811,623 shares, representing 36.60% of Art", "url": "https://www.gurufocus.com/news/8924437/ra-capital-management-lp-increases-stake-in-artiva-biotherapeutics-inc", "source_name": "GuruFocus", "published_at": "2026-06-20T01:10:05", "published_display": "20 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Inc (ARTV) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "Artiva Biotherapeutics Inc (ARTV) has a current price momentum score of 8.92, ranking 67th in the Biotechnology & Medical Research industry. The stock is trading between a resistance level of $11.40 and a support level of $7.53, suggesting it's suitable for range-bound swing trad", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-artv/technical", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:11", "published_display": "18 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Inc (ARTV) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Artiva Biotherapeutics Inc (ARTV) has an earnings forecast score of 8.67, ranking 71 out of 388 in its industry, with an average analyst price target of $18.00. Six analysts recommend a \"Buy\" for ARTV, with a high target of $23.00 and a low of $10.00. The company's previous quart", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-artv/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:11", "published_display": "18 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Inc (ARTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Artiva Biotherapeutics Inc (ARTV), though it notes that relevant data for business segments and regional profit contribution has not yet been disclosed by the company. It briefly shows the stock's price, market cap, an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-artv/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:20", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra capital acquires $4.6m in Artiva Biotherapeutics shares", "summary": "RA Capital Healthcare Fund, L.P. recently acquired 531,326 shares of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) for approximately $4.6 million through three transactions between June 12 and June 16, 2026. This buying activity occurred as ARTV shares surged 341% over the past yea", "url": "https://www.investing.com/news/insider-trading-news/ra-capital-acquires-46m-in-artiva-biotherapeutics-shares-93CH-4746113", "source_name": "Investing.com", "published_at": "2026-06-17T16:10:29", "published_display": "17 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics(ARTV.US) 10% Shareholder Buys US$4.6 Million in Common Stock", "summary": "A 10% shareholder of Artiva Biotherapeutics (ARTV.US) recently purchased common stock worth approximately US$4.6 million. This significant insider transaction indicates increased confidence from a major stakeholder in the company's future prospects. Such large investments by key ", "url": "https://www.moomoo.com/news/post/71622314/artiva-biotherapeutics-artvus-10-shareholder-buys-us-4-6-million", "source_name": "Moomoo", "published_at": "2026-06-16T22:10:59", "published_display": "16 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$ARTV stock is up 13% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQNHR1ejVpeE9VMVFnQXhpaEtKSEQ5YlUtTHFrUlBWV0c1eWUyaXZrTEhDdlNHRWZ6dl85cllBeWR0Y1JneGR0MzJuYkEtMWpnbXV0YVdqYm1KQ0piUFJsNDFuZy1YUllwRVc1NFlzRDVrbmNDOXNXUkFxU0dDUV9NY1I4alAzMHVxc21hbnB2OHpMS3dSNEN3ZTd6eXNrWnFi?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock By Investing.com", "summary": "RA Capital Management and its affiliated funds have acquired approximately $7.65 million worth of Artiva Biotherapeutics (NASDAQ: ARTV) common stock across several transactions between June 9 and June 11, 2026. These purchases increased the funds' indirect holdings, coinciding wi", "url": "https://au.investing.com/news/insider-trading-news/ra-capital-funds-acquire-765m-in-artiva-biotherapeutics-stock-93CH-4483873", "source_name": "Investing.com Australia", "published_at": "2026-06-12T13:40:29", "published_display": "12 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock", "summary": "RA Capital Management and its affiliated funds have acquired approximately $7.65 million worth of Artiva Biotherapeutics (NASDAQ: ARTV) common stock between June 9 and June 11, 2026. These purchases increase RA Capital Healthcare Fund's indirect holdings to over 16 million shares", "url": "https://www.investing.com/news/insider-trading-news/ra-capital-funds-acquire-765m-in-artiva-biotherapeutics-stock-93CH-4738684", "source_name": "Investing.com", "published_at": "2026-06-12T13:38:53", "published_display": "12 Jun 2026 13:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva: Targeting A New Benchmark In Refractory Rheumatoid Arthritis With AlloNK", "summary": "Artiva Biotherapeutics Inc. (ARTV) shares have dropped significantly from their 52-week high, currently trading around $8. The biotechnology company is developing AlloNK, a deep B-cell-depleting therapy, for patients with refractory rheumatoid arthritis who have not responded to ", "url": "https://www.rttnews.com/3659927/artiva-targeting-a-new-benchmark-in-refractory-rheumatoid-arthritis-with-allonk.aspx", "source_name": "RTTNews", "published_at": "2026-06-12T10:10:00", "published_display": "12 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Reports Positive AlloNK Data Across Autoimmune Diseases at EULAR 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/artiva-biotherapeutics-reports-positive-allonk-111706104.html", "source_name": "MT Newswires", "published_at": "2026-06-08T11:17:06+00:00", "published_display": "08 Jun 2026 11:17", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Highlights AlloNK\u00ae Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwJBVV95cUxObllzRl9pWWozXzQ0bEg4SldQbm9lWG1jOEVyWDBjZG9Gc1g3cU1zbnlFVlptNlVnNEVLUW5DVWJoRVNGZlBheTliWXUyVmpwQUp3U3IyRGh1TXZhYktSWTktYUdISU1EVzJReVRtQUFuanJBWFgyNnpWU0Y3VXZ6LTh4ekZ6WUtaTXlENWJUSXViTV9CaC0wOTNGaGJVdDNVelJxNlp6bmt2dk51TFh0ZVVuTHB3QUluT1FiZG8yTXFFVG45Qmc1V192cmROVXNsWnBaMm1LY2JPREsyOTUwWlBTSUZmbWU5clBYdXcydV9RNEE4WjVDUnFuSHRvczd0S041M0h2ZjZNTkl1WWhkRExxczYzYXVmaHpZWkJQVFBNTVRneUIxLWl2b1pRSVVYQXMxNUdUSHRpM0k?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/artiva-biotherapeutics-participate-2026-jefferies-120000007.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:00:00+00:00", "published_display": "28 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Purchase: 10% owner at $ARTV Buys 347,222 Shares | ARTV Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOOVBtZGNjXzZVZWxFMzlJZW5UQUlmdEhKSUVMQmN2S0kyenM3Z3N3N3JnSWJYYWlUM0J3ZEIxWm1HVjBYOE5fN3JWa3loQ3FoQW9DTm1mODFWZm9iNUVJQi1ITmpVOG9QcWtwM2dyTk1FT0F5cEc5N1FpVDAyZXNpc0FuYWxzN2ZDY0FLU2VlVGtVRlNGMnF1TEtsV3VDZw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold Artiva Biotherapeutics Shares Recently?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Announces Multiple AlloNK\u00ae Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/artiva-biotherapeutics-announces-multiple-allonk-200500767.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T20:05:00+00:00", "published_display": "19 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Appoints Diego Miralles as President", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/artiva-biotherapeutics-appoints-diego-miralles-125714835.html", "source_name": "MT Newswires", "published_at": "2026-05-19T12:57:14+00:00", "published_display": "19 May 2026 12:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/artiva-biotherapeutics-appoints-veteran-biotech-120000429.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T12:00:00+00:00", "published_display": "19 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wedbush Adjusts Price Target on Artiva Biotherapeutics to $40 From $23, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/wedbush-adjusts-price-target-artiva-122856141.html", "source_name": "MT Newswires", "published_at": "2026-05-08T12:28:56+00:00", "published_display": "08 May 2026 12:28", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARTV Stock Pares Majority Of Pre-Market Gains \u2013 $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNakpLdGRRWklkSWN3TEJoQjc1cTVXZTk1ZlN0aVkyUjluTHBkb3BvQW1yQTFFdlhjckxVSFJaX2JuYUt5czZnZU9wNjJBSUhSYlFNWHMwdU9lbGdacWZybDVXNnBVN0R5Z2ZuUWs0dnhyeThMNVpRN1h1aUZKZW5lWkZpWWRzenV0X3kwQmYxYVZMMEp2MVpLSjI3T3pfWWY3ekVTVTJNZGFfNlNnTDg0V2EzMFYxN0NNc3pub1FqMjVVQzI0SDk0ODlB?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOdkxKMEdKRk53bzhhTXJ1cXJFZm5YbVVFajZIczRCUFJXbU1GNlRta09Sc0dwOTlQR1RLNy1RYXFhTUdfU0tuZ2s2RmNza0t1d0lIVWhoWGlISHpDMTN5Y1M2Y3Z5dVh2RDdlTWZpN1RPa29oMWo5andSNGRZVWpWNXlxMjNzVjFxM0sxUmR5MTlQZTBmUEdXUW1JaVZUMmFhZUpTY0VjMDg0STN0NnF1VWd3UUU?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Announces Pricing of $300 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxNa2JTRGl2N2ZTMm9DS1dKeTlCQlNHU1oyTTlER19ZTTEwcGxBblZ0WE5UUEhNYjNXaWtZRlVySDBKdVlPS1ltZDM5bzVhS25YRGlVQ2Rlc0FUVV9pbW9SdnJESVcyRXd4OFk3cThvOEJ2eWhqa3ZfUTA2QmYyWUotTmE4Q1hnalRiS0R0eDZyQ00zbDJKSnBWVGRCYTBjOS1Qb0xSNF9yYWNDM3NJakZTVklwUWprTjBZaWJ6dkx5aDBqaVpzRm84ZTgwZzdBVVFNakp5QjJiQzJQR3lHTXV4Q25GNDRlZkVRVjh2TW9vUTdoc09UUXhad19FYktweHIwSDctMkRvd2M3bW1hejVmR1VvZ2hIOXl1?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva stock up on trial data for lead asset (ARTV:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQTGFYaTdJUnJFakJjY21DMkpTZEJZeko2ZDJIT2FDR3lJU2NJNEFLcDNhQVdoY01uQ09TS25Cd0dHdHNFY2w5c2doWXpNenA3a0xrNEp6SlhGWnU0ck41Slk2YTV6QWJOY3liczlvVTRWeW15ZDVYTm5ZVnkwaHRYMg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxQMFVha2psVHgtVU81RFFmejhDU1dOWGNkT1hFcF9SeTRJTmVHNE8ta1dVVk5Ha09USWtQenRLMlplbEpHQUw4ZlZSZjJCNlhYRFZfWEc4ZWUwVGhrQjJrdjZBV2wxUUp1S3h4ZjZUMHM5ZDM0SUNDbVBjV2lGcjJFWHlqVERsSlFaUVdrLXVKZ09jY1Y4OEpQNmlwOXBrRktZcjAxYWQ4RWthU2QzVTJrQ3k1eXZiMWtIdTMxSFRQYkNoQXE5ZWZPekFicl9iZ3J0Uk5JZEpNMVg5WmtCYlBEYUtfN0djaU4yQmFsUVV4VXNNaF9xSTRwMkt0dzhBY1E?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNeEwzcmRfNjNkSHR6RDVlZXk5dUZYZXoxV3F1UGJQcmpLSWwzVDhuUnpEak0ydEVCVktKckdiS0hKek1VTmdxWk8xdU1aaXROdWNzZ2twSlB5WjQ1OUJqRTNWRmVLcERkMmxEektPM0hXeE5CWGVicy1PQy1URkZNclN2YzN3eXdTWDNoV2hXNWRMbWk5SGZjV2k4WUlqZ3hzS20zeVlkMVh2SFhVV2pUa2RTNA?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQT1RvTmJ6bUtZTzdndWctZ1BjclZXUVVRak8wTUQxSWFKSHRHTGF5LXBYUXB0bEVVZ1ZBNVZjWWxaSWVQa2IxZTlSbl9iZHRJel9nRkFjR3cyZU4wREViQldxbk1UU0paWTEycE83S1dwX1kzQWlxNlktazZySXNLTl9NSERqYWNKeGl6QlJ5MzFZTTVuMEpDWlYzbXV2UHhpM21vUkI2UQ?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Ra Capital Management funds buy $194k in Artiva Biotherapeutics stock By Investing.com", "summary": "RA Capital Management funds recently acquired an additional $194,039 worth of Artiva Biotherapeutics (NASDAQ:ARTV) common stock over two days, increasing their already significant stake. These purchases involved shares bought at prices ranging from $8.94 to $8.97, even as Investi", "url": "https://m.za.investing.com/news/stock-market-news/ra-capital-management-funds-buy-194k-in-artiva-biotherapeutics-stock-93CH-4369073?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-15T00:12:25", "published_display": "15 Jul 2026 00:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra Capital Management funds buy $194k in Artiva Biotherapeutics stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOcXNYUmZkYTJzTm5SVmR5ZlF0cHltblpyam9IeUF5bkRQRDdIYjRZYWEtblZmN3RvekgxeDN4STUxcVNMc3Baem9PZVBvZXNoa0Q0dHg3amlyWkIyT0t4SlFsY3RsNk5FZkx2QVQ5M3o3aGJ0ZU44bFluUEFxQ3VMWnU4YU5BYXphbFJuX2F1TFJkc0Zyb2dXTEU0ZXFEWklHU3FNZFBKWlJQSjVRM2VmVGlfSXBrX2R2Y19oYWltOWRjN2IzMGtrbQ?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-14T23:04:00+00:00", "published_display": "14 Jul 2026 23:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?", "summary": "Artiva Biotherapeutics, Inc. (ARTV) is significantly outperforming the Medical sector and its specific industry (Medical - Biomedical and Genetics) this year, with a year-to-date return of 121% compared to the sector's 2.8% and the industry's 7.4%. The company holds a Zacks Rank ", "url": "https://finance.yahoo.com/healthcare/articles/artiva-biotherapeutics-inc-artv-outperforming-134002494.html", "source_name": "Market source", "published_at": "2026-07-08T08:40:00", "published_display": "08 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Artiva Biotherapeutics, Inc. (ARTV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1MZFlINzg4dmQzN1BlSDR4ZDdkNnMxNmlrN2x5THVuNXAzS2xPZnJjUWdXVk5iMnl0UmF6UExwQnB6NnVZekZiTHczc1NMS1dZZUFWanUxRXl2VTFvQkp6SWMwYkd0QzE4UlgyYQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What date does Artiva Biotherapeutics, Inc.'s (ARTV) report Earnings - Earnings Calendar & Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTFBnYnVIeTJCOFdFemFxOVNrUTdpM3dxVHhRVF9tenJVaGg4a1NYb1ZGbFh3UUhuaU00b0lXd3JUVWJHZ21zVHA1b2pHdjhrbi11ZmpHMzU4a2E3OUx1dnhIdE9wVXB2RmZ3cEhr?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Artiva Biotherapeutics Inc For: 29 June By Investing.com", "summary": "This article reports on a Form 4 filing for Artiva Biotherapeutics Inc (ARTV) for June 29, 2026. Form 4 filings typically disclose transactions by corporate insiders. The article provides the date of the filing and mentions the company's stock symbol and current trading performan", "url": "https://ng.investing.com/news/stock-market-news/form-4-artiva-biotherapeutics-inc-for-29-june-93CH-2578839", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T08:42:17", "published_display": "30 Jun 2026 08:42", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra capital funds buy $292k Artiva Biotherapeutics stock in late June", "summary": "Investment funds associated with RA Capital Management, L.P. recently purchased approximately $292,126 worth of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) stock. This comes as Artiva's shares have surged over 554% in the last year, and the company has received a Regenerative Medi", "url": "https://www.investing.com/news/insider-trading-news/ra-capital-funds-buy-292k-artiva-biotherapeutics-stock-in-late-june-93CH-4766254", "source_name": "Investing.com", "published_at": "2026-06-29T21:42:17", "published_display": "29 Jun 2026 21:42", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Index", "summary": "Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV) has been added to the Russell 2000 Index, as well as several related Russell indices including the Russell 2500 Growth, Russell 2000 Value, and Russell 3000 Index. This inclusion marks a significant milestone for the clinical-stage bi", "url": "https://www.marketscreener.com/news/artiva-biotherapeutics-inc-nasdaqgm-artv-added-to-russell-2000-index-ce7f5fdfdc8fff27", "source_name": "marketscreener.com", "published_at": "2026-06-29T17:52:00", "published_display": "29 Jun 2026 17:52", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Value Benchmark", "summary": "Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV) has been added to the Russell 2000 Value Benchmark. The company is a clinical-stage biotechnology firm specializing in natural killer (NK) cell-based therapies for autoimmune diseases and cancers. Its lead product candidate, AlloNK, i", "url": "https://www.marketscreener.com/news/artiva-biotherapeutics-inc-nasdaqgm-artv-added-to-russell-2000-value-benchmark-ce7f5fdfd880ff27", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:39:53", "published_display": "29 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 3000E Growth Benchmark", "summary": "Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV) has been added to the Russell 3000E Growth Benchmark. This move signifies recognition within a broad market index, suggesting increased visibility and potential for investment. The company specializes in developing clinical-stage, nat", "url": "https://www.marketscreener.com/news/artiva-biotherapeutics-inc-nasdaqgm-artv-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8cf120", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:39:52", "published_display": "29 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Growth Benchmark", "summary": "Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV), a clinical-stage biotechnology company, has been added to the Russell 2000 Growth Benchmark index. This inclusion highlights the company's focus on developing NK cell-based therapies for autoimmune diseases and cancers. The article a", "url": "https://www.marketscreener.com/news/artiva-biotherapeutics-inc-nasdaqgm-artv-added-to-russell-2000-growth-benchmark-ce7f5fded18df121", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:33:00", "published_display": "29 Jun 2026 07:33", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Artiva Biotherapeutics, Inc. \u2013 NASDAQ:ARTV", "summary": "This article provides financial information for Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or an incomplete data point from a financial charting platform like TradingView, with no further details", "url": "https://www.tradingview.com/symbols/NASDAQ-ARTV/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:11:17", "published_display": "28 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Artiva Biotherapeutics, Inc. \u2013 NASDAQ:ARTV", "summary": "The article provides a title related to the \"Price to book forward\" for Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) and lists various financial and market data services and tools available on the TradingView platform. However, the body of the article appears to primarily consist ", "url": "https://www.tradingview.com/symbols/NASDAQ-ARTV/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T15:10:25", "published_display": "28 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Artiva Biotherapeutics, Inc. \u2013 NASDAQ:ARTV", "summary": "This page displays the enterprise value to EBITDA forward for Artiva Biotherapeutics, Inc. (NASDAQ: ARTV). It presents financial data, market information, and related company details. The content is primarily a data presentation from TradingView, including a historical overview, ", "url": "https://www.tradingview.com/symbols/NASDAQ-ARTV/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:41:39", "published_display": "27 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference", "summary": "Artiva Biotherapeutics announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. Management will host a fireside chat on June 30, 2026, to discuss the company's clinical-stage cell therapies for autoimmune diseases, including their lead progra", "url": "https://finance.yahoo.com/healthcare/articles/artiva-biotherapeutics-participate-h-c-200500499.html", "source_name": "Market source", "published_at": "2026-06-26T22:10:17", "published_display": "26 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARTV Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast for Artiva Biotherapeutics, Inc. (ARTV) stock, including analyst price targets, historical performance, earnings information, and financial data. It highlights that analysts have a maximum price estimate of $41.00 and a minimum of $23.00 ", "url": "https://www.tradingview.com/symbols/NASDAQ-ARTV/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:10", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics, Inc. Actuals & Estimates (NASDAQ:ARTV)", "summary": "This article provides a detailed financial overview and analyst estimates for Artiva Biotherapeutics, Inc. (NASDAQ: ARTV). It covers the company's financial performance, stock price movements, future forecasts, and key metrics such as market capitalization and earnings reports. T", "url": "https://www.tradingview.com/symbols/NASDAQ-ARTV/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:10", "published_display": "25 Jun 2026 18:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Inc (ARTV) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Artiva Biotherapeutics Inc (ARTV), which currently holds a weak financial score of 5.40, ranking low within the Biotechnology & Medical Research industry. Key financial metrics related to profitability, operational efficiency, and gro", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-artv/financial-health", "source_name": "TradingKey", "published_at": "2026-06-24T06:11:10", "published_display": "24 Jun 2026 06:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA CAPITAL MANAGEMENT, L.P. Increases Stake in Artiva Biotherape", "summary": "RA CAPITAL MANAGEMENT, L.P. has significantly increased its stake in Artiva Biotherapeutics Inc. by acquiring an additional 1,434,155 shares. This transaction, executed on June 11, 2026, at $8 per share, brings their total holdings to 17,811,623 shares, representing 36.60% of Art", "url": "https://www.gurufocus.com/news/8924437/ra-capital-management-lp-increases-stake-in-artiva-biotherapeutics-inc", "source_name": "GuruFocus", "published_at": "2026-06-20T01:10:05", "published_display": "20 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Inc (ARTV) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "Artiva Biotherapeutics Inc (ARTV) has a current price momentum score of 8.92, ranking 67th in the Biotechnology & Medical Research industry. The stock is trading between a resistance level of $11.40 and a support level of $7.53, suggesting it's suitable for range-bound swing trad", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-artv/technical", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:11", "published_display": "18 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Inc (ARTV) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Artiva Biotherapeutics Inc (ARTV) has an earnings forecast score of 8.67, ranking 71 out of 388 in its industry, with an average analyst price target of $18.00. Six analysts recommend a \"Buy\" for ARTV, with a high target of $23.00 and a low of $10.00. The company's previous quart", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-artv/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:11", "published_display": "18 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Inc (ARTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Artiva Biotherapeutics Inc (ARTV), though it notes that relevant data for business segments and regional profit contribution has not yet been disclosed by the company. It briefly shows the stock's price, market cap, an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-artv/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:20", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra capital acquires $4.6m in Artiva Biotherapeutics shares", "summary": "RA Capital Healthcare Fund, L.P. recently acquired 531,326 shares of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) for approximately $4.6 million through three transactions between June 12 and June 16, 2026. This buying activity occurred as ARTV shares surged 341% over the past yea", "url": "https://www.investing.com/news/insider-trading-news/ra-capital-acquires-46m-in-artiva-biotherapeutics-shares-93CH-4746113", "source_name": "Investing.com", "published_at": "2026-06-17T16:10:29", "published_display": "17 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics(ARTV.US) 10% Shareholder Buys US$4.6 Million in Common Stock", "summary": "A 10% shareholder of Artiva Biotherapeutics (ARTV.US) recently purchased common stock worth approximately US$4.6 million. This significant insider transaction indicates increased confidence from a major stakeholder in the company's future prospects. Such large investments by key ", "url": "https://www.moomoo.com/news/post/71622314/artiva-biotherapeutics-artvus-10-shareholder-buys-us-4-6-million", "source_name": "Moomoo", "published_at": "2026-06-16T22:10:59", "published_display": "16 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$ARTV stock is up 13% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQNHR1ejVpeE9VMVFnQXhpaEtKSEQ5YlUtTHFrUlBWV0c1eWUyaXZrTEhDdlNHRWZ6dl85cllBeWR0Y1JneGR0MzJuYkEtMWpnbXV0YVdqYm1KQ0piUFJsNDFuZy1YUllwRVc1NFlzRDVrbmNDOXNXUkFxU0dDUV9NY1I4alAzMHVxc21hbnB2OHpMS3dSNEN3ZTd6eXNrWnFi?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock By Investing.com", "summary": "RA Capital Management and its affiliated funds have acquired approximately $7.65 million worth of Artiva Biotherapeutics (NASDAQ: ARTV) common stock across several transactions between June 9 and June 11, 2026. These purchases increased the funds' indirect holdings, coinciding wi", "url": "https://au.investing.com/news/insider-trading-news/ra-capital-funds-acquire-765m-in-artiva-biotherapeutics-stock-93CH-4483873", "source_name": "Investing.com Australia", "published_at": "2026-06-12T13:40:29", "published_display": "12 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock", "summary": "RA Capital Management and its affiliated funds have acquired approximately $7.65 million worth of Artiva Biotherapeutics (NASDAQ: ARTV) common stock between June 9 and June 11, 2026. These purchases increase RA Capital Healthcare Fund's indirect holdings to over 16 million shares", "url": "https://www.investing.com/news/insider-trading-news/ra-capital-funds-acquire-765m-in-artiva-biotherapeutics-stock-93CH-4738684", "source_name": "Investing.com", "published_at": "2026-06-12T13:38:53", "published_display": "12 Jun 2026 13:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva: Targeting A New Benchmark In Refractory Rheumatoid Arthritis With AlloNK", "summary": "Artiva Biotherapeutics Inc. (ARTV) shares have dropped significantly from their 52-week high, currently trading around $8. The biotechnology company is developing AlloNK, a deep B-cell-depleting therapy, for patients with refractory rheumatoid arthritis who have not responded to ", "url": "https://www.rttnews.com/3659927/artiva-targeting-a-new-benchmark-in-refractory-rheumatoid-arthritis-with-allonk.aspx", "source_name": "RTTNews", "published_at": "2026-06-12T10:10:00", "published_display": "12 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Reports Positive AlloNK Data Across Autoimmune Diseases at EULAR 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/artiva-biotherapeutics-reports-positive-allonk-111706104.html", "source_name": "MT Newswires", "published_at": "2026-06-08T11:17:06+00:00", "published_display": "08 Jun 2026 11:17", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Highlights AlloNK\u00ae Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwJBVV95cUxObllzRl9pWWozXzQ0bEg4SldQbm9lWG1jOEVyWDBjZG9Gc1g3cU1zbnlFVlptNlVnNEVLUW5DVWJoRVNGZlBheTliWXUyVmpwQUp3U3IyRGh1TXZhYktSWTktYUdISU1EVzJReVRtQUFuanJBWFgyNnpWU0Y3VXZ6LTh4ekZ6WUtaTXlENWJUSXViTV9CaC0wOTNGaGJVdDNVelJxNlp6bmt2dk51TFh0ZVVuTHB3QUluT1FiZG8yTXFFVG45Qmc1V192cmROVXNsWnBaMm1LY2JPREsyOTUwWlBTSUZmbWU5clBYdXcydV9RNEE4WjVDUnFuSHRvczd0S041M0h2ZjZNTkl1WWhkRExxczYzYXVmaHpZWkJQVFBNTVRneUIxLWl2b1pRSVVYQXMxNUdUSHRpM0k?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/artiva-biotherapeutics-participate-2026-jefferies-120000007.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:00:00+00:00", "published_display": "28 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Purchase: 10% owner at $ARTV Buys 347,222 Shares | ARTV Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOOVBtZGNjXzZVZWxFMzlJZW5UQUlmdEhKSUVMQmN2S0kyenM3Z3N3N3JnSWJYYWlUM0J3ZEIxWm1HVjBYOE5fN3JWa3loQ3FoQW9DTm1mODFWZm9iNUVJQi1ITmpVOG9QcWtwM2dyTk1FT0F5cEc5N1FpVDAyZXNpc0FuYWxzN2ZDY0FLU2VlVGtVRlNGMnF1TEtsV3VDZw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold Artiva Biotherapeutics Shares Recently?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Announces Multiple AlloNK\u00ae Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/artiva-biotherapeutics-announces-multiple-allonk-200500767.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T20:05:00+00:00", "published_display": "19 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Appoints Diego Miralles as President", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/artiva-biotherapeutics-appoints-diego-miralles-125714835.html", "source_name": "MT Newswires", "published_at": "2026-05-19T12:57:14+00:00", "published_display": "19 May 2026 12:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/artiva-biotherapeutics-appoints-veteran-biotech-120000429.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T12:00:00+00:00", "published_display": "19 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Adjusts Price Target on Artiva Biotherapeutics to $40 From $23, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/wedbush-adjusts-price-target-artiva-122856141.html", "source_name": "MT Newswires", "published_at": "2026-05-08T12:28:56+00:00", "published_display": "08 May 2026 12:28", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARTV Stock Pares Majority Of Pre-Market Gains \u2013 $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNakpLdGRRWklkSWN3TEJoQjc1cTVXZTk1ZlN0aVkyUjluTHBkb3BvQW1yQTFFdlhjckxVSFJaX2JuYUt5czZnZU9wNjJBSUhSYlFNWHMwdU9lbGdacWZybDVXNnBVN0R5Z2ZuUWs0dnhyeThMNVpRN1h1aUZKZW5lWkZpWWRzenV0X3kwQmYxYVZMMEp2MVpLSjI3T3pfWWY3ekVTVTJNZGFfNlNnTDg0V2EzMFYxN0NNc3pub1FqMjVVQzI0SDk0ODlB?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOdkxKMEdKRk53bzhhTXJ1cXJFZm5YbVVFajZIczRCUFJXbU1GNlRta09Sc0dwOTlQR1RLNy1RYXFhTUdfU0tuZ2s2RmNza0t1d0lIVWhoWGlISHpDMTN5Y1M2Y3Z5dVh2RDdlTWZpN1RPa29oMWo5andSNGRZVWpWNXlxMjNzVjFxM0sxUmR5MTlQZTBmUEdXUW1JaVZUMmFhZUpTY0VjMDg0STN0NnF1VWd3UUU?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Announces Pricing of $300 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxNa2JTRGl2N2ZTMm9DS1dKeTlCQlNHU1oyTTlER19ZTTEwcGxBblZ0WE5UUEhNYjNXaWtZRlVySDBKdVlPS1ltZDM5bzVhS25YRGlVQ2Rlc0FUVV9pbW9SdnJESVcyRXd4OFk3cThvOEJ2eWhqa3ZfUTA2QmYyWUotTmE4Q1hnalRiS0R0eDZyQ00zbDJKSnBWVGRCYTBjOS1Qb0xSNF9yYWNDM3NJakZTVklwUWprTjBZaWJ6dkx5aDBqaVpzRm84ZTgwZzdBVVFNakp5QjJiQzJQR3lHTXV4Q25GNDRlZkVRVjh2TW9vUTdoc09UUXhad19FYktweHIwSDctMkRvd2M3bW1hejVmR1VvZ2hIOXl1?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva stock up on trial data for lead asset (ARTV:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQTGFYaTdJUnJFakJjY21DMkpTZEJZeko2ZDJIT2FDR3lJU2NJNEFLcDNhQVdoY01uQ09TS25Cd0dHdHNFY2w5c2doWXpNenA3a0xrNEp6SlhGWnU0ck41Slk2YTV6QWJOY3liczlvVTRWeW15ZDVYTm5ZVnkwaHRYMg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxQMFVha2psVHgtVU81RFFmejhDU1dOWGNkT1hFcF9SeTRJTmVHNE8ta1dVVk5Ha09USWtQenRLMlplbEpHQUw4ZlZSZjJCNlhYRFZfWEc4ZWUwVGhrQjJrdjZBV2wxUUp1S3h4ZjZUMHM5ZDM0SUNDbVBjV2lGcjJFWHlqVERsSlFaUVdrLXVKZ09jY1Y4OEpQNmlwOXBrRktZcjAxYWQ4RWthU2QzVTJrQ3k1eXZiMWtIdTMxSFRQYkNoQXE5ZWZPekFicl9iZ3J0Uk5JZEpNMVg5WmtCYlBEYUtfN0djaU4yQmFsUVV4VXNNaF9xSTRwMkt0dzhBY1E?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNeEwzcmRfNjNkSHR6RDVlZXk5dUZYZXoxV3F1UGJQcmpLSWwzVDhuUnpEak0ydEVCVktKckdiS0hKek1VTmdxWk8xdU1aaXROdWNzZ2twSlB5WjQ1OUJqRTNWRmVLcERkMmxEektPM0hXeE5CWGVicy1PQy1URkZNclN2YzN3eXdTWDNoV2hXNWRMbWk5SGZjV2k4WUlqZ3hzS20zeVlkMVh2SFhVV2pUa2RTNA?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQT1RvTmJ6bUtZTzdndWctZ1BjclZXUVVRak8wTUQxSWFKSHRHTGF5LXBYUXB0bEVVZ1ZBNVZjWWxaSWVQa2IxZTlSbl9iZHRJel9nRkFjR3cyZU4wREViQldxbk1UU0paWTEycE83S1dwX1kzQWlxNlktazZySXNLTl9NSERqYWNKeGl6QlJ5MzFZTTVuMEpDWlYzbXV2UHhpM21vUkI2UQ?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 69, "sentiment_summary": {"positive": 26, "negative": 5, "neutral": 38, "score": 57, "total": 69, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 26.5, "count": 45}, {"event": "earnings", "label": "Earnings", "weight": 10.54, "count": 19}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 26, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 9.64, "latest_week": "2026-07-10", "one_week_move": 0.3, "four_week_move": 12.9, "twelve_week_move": -23.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.038227, "market_dynamics_buy_signal": false, "relative_strength": 55.881321, "fair_value_gap": 49.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.392, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.3% over one week, +12.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingView", "count": 7}, {"label": "GlobeNewswire", "count": 6}, {"label": "TradingKey", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Quiver Quantitative", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 62}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 45}, {"label": "Earnings", "count": 19}, {"label": "Deals and strategy", "count": 3}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "62", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "8", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.3% over one week, +12.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Ra Capital Management funds buy $194k in Artiva Biotherapeutics stock By Investing.com"}], "updated_at": "2026-07-16T11:42:21.904352+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}